logo-loader
viewQ BioMed Inc.

Q BioMed gets US patent for its Uttrocide-B molecule as a potential liver cancer treatment

Q BioMed Inc (OTCQB:QBIO) CEO Denis Corin tells Proactive it has received a US patent for its Uttrocide-B molecule as a potential liver cancer treatment.

Corin says the company now has the exclusive rights to the technology through an agreement with the Rajiv Gandhi Centre for Biotechnology, an autonomous institute under the Department of Biotechnology, Government of India and the Oklahoma Medical Research Foundation.

The group has now begun scaling up manufacturing and preparing Uttroside-B for an investigational new drug (IND) application with the FDA.

Quick facts: Q BioMed Inc.

Price: 1.07 USD

OTCQB:QBIO
Market: OTCQB
Market Cap: $25.05 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc. named herein, including the promotion by the Company of Q BioMed Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Norman Broadbent secures new loan facility

Norman Broadbent PLC (LON:NBB), the executive search group, has strengthened its balance sheet with a £250,000 six-year CBILS loan. The funds can be drawn at any point before January 16 2021, with a 12 month interest-free period following drawdown, after which an interest rate of 4.75% per...

1 day, 2 hours ago

2 min read